Skip to content

An open randomised trial to evaluate different therapeutic strategies of combination therapy for human immunodeficiency virus (HIV-1) Infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN44582462
Enrollment
1000
Registered
2005-09-28
Start date
1999-03-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV-1 infection Infections and Infestations Human immunodeficiency virus (HIV)

Interventions

Randomisation of approximately 1000 participants, from 17 countries worldwide, to one of three drug regimens: 1. 2 NRTIs plus a NNRTI 2. 2 NRTIs plus a PI 3. 2 NRTIs plus a NNRTI and PI Quality of li

Sponsors

Medical Research Council (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The participants in the trial must be HIV-1 infected, over 18 years of age, at any stage of HIV disease, but not acute symptomatic primary infection, where anti-retroviral therapy is indicated. Participants should be likely to take their first regimen for at least 6 months and be expected to adhere to the protocol.

Exclusion criteria

Exclusion criteria: 1. The participants must not have received prior treatment with antiretroviral drugs or immunotherapy 2. There must be no history of peripheral neuropathy or pancreatitis 3. Individuals must not be receiving combination cytotoxic chemotherapy for cancer or parental therapy for an active opportunistic infection 4. Women should not be pregnant, breastfeeding or unwilling to use adequate contraception 5. Participants will be ineligible if biochemistry and haematology blood results from screening are outside the trial upper safety limits.

Design outcomes

Primary

MeasureTime frame
1. Change in CD4 cell count between 2 and 3 years 2. The proportion of patients with plasma HIV RNA below 50 copies/ml at 3 years

Secondary

MeasureTime frame
1. Change in CD4 cell count between 2 and 3 years 2. Change in plasma HIV RNA at 3 years 3. The time on first regimen 4. Time on second regimen (where applicable) 5. The time to first plasma HIV RNA below 50 copies/ml 6. Phenotypic and genotypic drug resistance at 3 years 7. Progression of HIV disease (including death)

Countries

Australia, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, New Zealand, Portugal, Spain, Sweden, Switzerland, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 11, 2026